Infinimmune
Infinimmune is pioneering the development of drugs from complete human antibodies, utilizing its unique Complete Human™ technology and the Anthrobody™ platform. The company focuses on discovering, characterizing, and advancing therapeutic antibodies that are fully human, aiming to treat human diseases such as autoimmunity and cancer. Their approach emphasizes safety, efficacy, and the potential for novel therapeutics by leveraging the human immune system's natural responses.
Industries
Nr. of Employees
small (1-50)
Products
Validated interleukin program (autoimmunity)
Preclinical-stage therapeutic antibody program targeting an interleukin pathway for autoimmune disease; listed as a validated interleukin program in the company's pipeline.
Immuno-oncology discovery programs (undisclosed targets)
Discovery-stage programs applying human repertoire sequencing and analysis to identify antibody therapeutics for oncology indications; targets not publicly disclosed.
Validated interleukin program (autoimmunity)
Preclinical-stage therapeutic antibody program targeting an interleukin pathway for autoimmune disease; listed as a validated interleukin program in the company's pipeline.
Immuno-oncology discovery programs (undisclosed targets)
Discovery-stage programs applying human repertoire sequencing and analysis to identify antibody therapeutics for oncology indications; targets not publicly disclosed.
Services
Partnership engagements to perform deep B-cell sequencing and joint discovery of human-derived antibody candidates for therapeutic programs.
Machine-learning model trained on human antibody sequences to support antibody humanization, optimization, and sequence design workflows.
Partnership engagements to perform deep B-cell sequencing and joint discovery of human-derived antibody candidates for therapeutic programs.
Machine-learning model trained on human antibody sequences to support antibody humanization, optimization, and sequence design workflows.
Expertise Areas
- Therapeutic antibody discovery from human repertoires
- AI-driven antibody engineering and optimization
- Protein engineering and alternate antibody formats
- Single-cell and deep B-cell sequencing
Key Technologies
- Immunosequencing (B-cell repertoire sequencing)
- Single-cell sequencing
- Deep B-cell sequencing
- AI / machine learning for antibody design
News & Updates
Infinimmune has developed the GLIMPSE-1 AI model trained exclusively on human antibody sequences, enabling advanced therapeutic engineering.
An article discussing Infinimmune's innovative approaches to antibody engineering.
An insight article on the FDA's initiative to eliminate animal testing requirements for antibody drugs.
A report on the FDA's efforts to reduce animal testing in drug development.
An article about the FDA's goal to eliminate animal testing for antibody therapeutics.
Infinimmune announced a partnership with Grid Therapeutics to identify new antibody drug candidates for non-small cell lung cancer.
Infinimmune has developed the GLIMPSE-1 AI model trained exclusively on human antibody sequences, enabling advanced therapeutic engineering.
An article discussing Infinimmune's innovative approaches to antibody engineering.
An insight article on the FDA's initiative to eliminate animal testing requirements for antibody drugs.
A report on the FDA's efforts to reduce animal testing in drug development.
An article about the FDA's goal to eliminate animal testing for antibody therapeutics.
Infinimmune announced a partnership with Grid Therapeutics to identify new antibody drug candidates for non-small cell lung cancer.